Trou­bled Aveo hit with an­oth­er set­back as in­ves­ti­ga­tors shut­ter PhII

Aveo On­col­o­gy may be un­der new man­age­ment, but it’s still af­flict­ed by a long-run­ning pat­tern of trou­ble in the clin­ic. Usu­al­ly, that trou­ble has been fo­cused on its lead drug tivozanib. This time, though, the set­back is for its num­ber two drug in the clin­ic.

In a fil­ing with the SEC Mon­day morn­ing, the biotech $AVEO says that it was forced to dis­con­tin­ue a mid-stage study for fi­clatuzum­ab due to a high dis­con­tin­u­a­tion rate among a group of pa­tients in the drug arm. The drug is a he­pa­to­cyte growth fac­tor (HGF) in­hibito­ry an­ti­body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.